Compile Data Set for Download or QSAR
maximum 50k data
Found 105 Enz. Inhib. hit(s) with all data for entry = 10584
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552553(WO2022098970, Example 1)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552553(WO2022098970, Example 1)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552553(WO2022098970, Example 1)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552554(WO2022098970, Example 2 | WO2022098970, Example 9)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552554(WO2022098970, Example 2 | WO2022098970, Example 9)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552554(WO2022098970, Example 2 | WO2022098970, Example 9)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552555(WO2022098970, Example 3)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552555(WO2022098970, Example 3)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552555(WO2022098970, Example 3)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552556(WO2022098970, Example 4)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552556(WO2022098970, Example 4)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552556(WO2022098970, Example 4)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552557(WO2022098970, Example 5)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552557(WO2022098970, Example 5)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552557(WO2022098970, Example 5)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552558(WO2022098970, Example 6)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552558(WO2022098970, Example 6)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552558(WO2022098970, Example 6)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552559(WO2022098970, Example 7)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552559(WO2022098970, Example 7)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552559(WO2022098970, Example 7)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552560(WO2022098970, Example 8)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552560(WO2022098970, Example 8)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552560(WO2022098970, Example 8)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552554(WO2022098970, Example 2 | WO2022098970, Example 9)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552554(WO2022098970, Example 2 | WO2022098970, Example 9)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552554(WO2022098970, Example 2 | WO2022098970, Example 9)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552562(WO2022098970, Example 10)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552562(WO2022098970, Example 10)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552562(WO2022098970, Example 10)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552563(WO2022098970, Example 153)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552563(WO2022098970, Example 153)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552563(WO2022098970, Example 153)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552564(WO2022098970, Example 154)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552564(WO2022098970, Example 154)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552564(WO2022098970, Example 154)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552565(WO2022098970, Example 199)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552565(WO2022098970, Example 199)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552565(WO2022098970, Example 199)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552566(WO2022098970, Example 221)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552566(WO2022098970, Example 221)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552566(WO2022098970, Example 221)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552567(WO2022098970, Example 222)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552567(WO2022098970, Example 222)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552567(WO2022098970, Example 222)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552568(WO2022098970, Example 292)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552568(WO2022098970, Example 292)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552568(WO2022098970, Example 292)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552569(WO2022098970, Example 293)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly

WIPO
LigandPNGBDBM552569(WO2022098970, Example 293)
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
Displayed 1 to 50 (of 105 total ) | Next | Last >>
Jump to: